Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor for prevention of major cardiovascular events in high-risk type 2 diabetes mellitus
2013-003519-23Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), cardiac morbidity and stroke comparing Ticagrelor with Placebo (2 arms). Primary endpoint: Time to first major cardiovascular event. Started Nov 2013; status: completed.
02
Drugs
ticagrelor
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbiditystroke
Beyond the preview
Go deeper on 2013-003519-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003519-23.